<；P>；PROBLEM TO BE SOLVED: To provide an siRNA (small interference RNA) targeting a clinically applicable Akt gene. <；P>；SOLUTION: The siRNA is a double-stranded siRNA specifically targeting any of Akt1, Akt2 and Akt3 genes and is the double-stranded siRNA of 21 bases composed of 19 base pairs and 3'-terminal overhang of 2 bases or the double-stranded siRNA of a plant end composed of 27 base pairs. Since the double-stranded siRNA mediates the RNAi (RNA interference) specific for any of the Akt1, Akt2 and Akt3 genes while avoiding off-target effects and interferon responses, e.g. clinical application can be made. The siRNA is useful in the field of medicines or pharmaceutical compositions using the Akt1, Akt2 or Akt3 as a target molecule. e.g. the field of therapy or the pharmaceutical compositions related to cancer therapy including cancer in the oral cavity. <；P>；COPYRIGHT: (C)2007,JPO&INPIT
